Chronic Kidney Disease Requiring Chronic Dialysis Clinical Trial
Official title:
Contribution of Body Composition Monitor (BCM) Among Patients Using Daily Home Dialysis With Low Dialysate Flow : French Study Cohort
The fluid overload measured by the Body Composition Monitor (BCM Fresenius Medical Care) is a
new independent risk factor of mortality.
This risk has already been described in intermittent hemodialysis patients and peritoneal
dialysis patients but never evaluated in Daily Home Dialysis with low dialysate flow.
The investigator propose a first study measuring the state of hydration by impedancemetry
(BCM) in this population.
The aim of this work is to to analyze hydration status in a representative sample of
prevalent Daily Home Dialysis with low-flow Dialysate patients.
Secondary objectives are to identify associations between hydration status and patient
characteristics and treatment practice in order to find out which conditions should alert the
clinician to potential fluid overload, to compare these results with the peritoneal dialysis
population and in center hemodialysis population, to evaluate the correlation between
impedancemetry and blood pressure in this population, to assess the nutritional status and
evaluation of a new method of measurement of kt / V based on impedancemetry, without recourse
to a blood test.
Study objectives
This study is a cross sectional, observational trial in 11 centers in France. The primary
objective is to analyze hydration status in a representative sample of prevalent Daily Home
Dialysis with low-flow Dialysate patients.
Secondary objectives are to identify associations between hydration status and patient
characteristics and treatment practice in order to find out which conditions should alert the
clinician to potential fluid overload, to compare these results with the peritoneal dialysis
population and in center hemodialysis population, to evaluate the correlation between
impedancemetry and blood pressure in this population, to assess the nutritional status and
evaluation of a new method of measurement of kt / V based on impedancemetry, without recourse
to a blood test.
Centers
Participants in this study are: CHU de Caen, Tenon Hospital, CHG Saint-Lô, CHG Alençon, CHG
Flers, CHG Lisieux, CHG Evreux, ANIDER Rouen, CHG Le Havre, A.U.B Rennes, A.D.P.C Marseille.
Patients
In each center, all prevalent patients, for more than 3 months, on Daily Home Dialysis with
Low-flow Dialysate are assessed for eligibility for inclusion if they are older than 18 years
of age and want to sign informed consent. Patients are excluded if they have a cardiac
pacemaker or metallic implants, are amputees or are pregnant. Patients are evaluated during a
routine clinical visit. All patients will signed informed consent, and ethical advice is
obtained.
Measurements of hydration and body composition
BCM measurements will be performed in each center by one reference physician or nurse, using
a portable whole body bioimpedance spectroscopy device, the BCM (Fresenius Medical Care). The
BCM measures the impedance spectroscopy at 50 different frequencies between 5 kHz and 1 MHz.
The BCM was validated intensively against all available gold-standard methods.
The measurement will be performed in pre-dialysis, electrodes will be attached to one hand
and one foot at the ipsilateral side, after the patient will be in recumbent position for at
least 5 minutes. Reproducibility of BCM derived parameters is high, with a coefficient of
variation for the interobserver variability ECW and TBW around 1.2%. Therefore, only one BCM
measurement is performed in each individual patient.
Extracellular water (ECW), intracellular water (ICW) and total body water (TBW) are
determined from the measured impedance data following the model of Moissl et al en 2006.
Fluid overload is expressed by a compartment called OH (overhydration). OH represents the
difference between the amount of ECW in the tissue as actually detected by the BCM and the
amount of water present in tissue, as predicted by physiological models under normal
physiological (normohydrated) conditions. Of note, OH has no direct relation to circulating
volume.
Four hydrations groups are defined, based on studies by Wieskotten et al. on healthy
population and Wabel et al. on a dialysis population: Normohydrate group: OH between -1.1L
and + 1.1L (corresponding to the 10th and 90th percentiles of a population of the same gender
distribution and with a comparable age band out of a healthy reference cohort, where
hydration status was measured with the identical technology); Hypovolemic group: OH <-1.1L;
Fluid overload group: OH between + 1.1L and + 2.5L; Severe fluid overload group: OH> + 2.5L.
The post-dialysis OH status will be obtained by the difference between pre-dialysis OH
obtained by impedancemetry and the UF performed.
Blood pressure will be performed in pre-dialytic and post-dialytic and is recorded as the
mean of two consecutive measurements with 5 minutes interval, using one single calibrated
device in each center. The investigator defined 3 groups according to pre-dialysis systolic
blood pressure (SBP): Hypertensive: SBP > 140 mmHg; Normotendu: SBP [100-140 mmHg];
Hypotensive: SBP < 100 mmHg.
Height and weight will be measured using one single calibrated device in each center.
Clinically relevant parameters will be registered in the case report form (CRF).
Nutritional assessment
Nutritional status is evaluated using three methods:
The first one is The Mini Nutritional Assessment (MNA), on 30 points, is a questionnaire of
18 questions to define three groups: 24-30 points: normal nutritional status; 17-23.5 points:
risk of malnutrition and < 17 points: poor nutritional status.
The second one is the Scale of Assessment of the food intake (EPA) is a rapid tool based on
self-assessment by analog scale from 0 to 10. An EPA> 7 should result in nutritional
management.
The third is according to the impedancemetry. The BCM (Fresenius Medical Care), provides,
according to Chamney et al. Model, two parameters: "LTM" and "FTM" for "lean tissue mass" and
"fat tissue mass". The values obtained will be normalized to the body surface, to allow a
comparison between patients of different size, thus giving the lean tissue index (LTI = LTM /
height2) and the fat tissue index (FTI = FTM / height2). The values for LTI and FTI will be
compared to a healthy reference population matched by age and sex. Values below the 10th
percentile of the reference population will be considered clinically significant.
Résults were registered in the case report form (CRF).
Patient characteristics
All this information will be collected using two questionnaires given to one reference
physician or nurse and the patient respectively.
The investigator identified diabetes (assumed to be present in patients using glucose
lowering drugs or insulin), nephropathy, residual diuresis, comorbidities allowing the
calculation of the Charlson score, numbers of antihypertensive drugs, hospitalization less
than three months old, history of peritoneal dialysis and / or transplantation.
Concerning the daily practice of home dialysis the investigator identified ultrafiltration,
blood flow, length of sessions, type of vascular access and creation date, the usual time of
the session, the person performing the fistula puncture at home, needle type, frequent
problem with connection, observance of dialysis sessions, date of installation at home The
following biochemical parameters will be determined in the local laboratories from blood
collected during the routine visit. Predialytic dosage: hemoglobin, hematocrit, platelets,
leukocytes, urea, creatinine, serum iron, CST, ferritin, sodium, chlorine, potassium,
magnesium, alkaline reserve, protidemia, albumin, prealbumin, CRP, PTH, calcium, phosphorus,
BNP, B2-microglobulin. Postdialytic dosage: sodium, chlorine, potassium, alkaline reserve,
urea, protidemia, B2-microglobulin.
New Kt/V measurement method
Conventionally in dialysis patients, the dialysis dose is represented by the formula kt / V,
with: k= plasma clearance of urea; t= unit of time; V= volume of distribution of urea in
dialysis patient.
The current assessment is Daugirdas2: Kt / V = -ln (R- (0.008 * t) + ((4 (3.5 * R)) * UF%),
with: R= Urea after / Urea before; t= time of the session (hour); UF%= 100*/post-dialysis
weight, Our current method therefore requires a plasma dosage of urea at the beginning and
end of the session.
The investigator propose a new measurement method where the V will be obtained by
impedancemetry and the t corresponds to the duration of the session. For k, the investigator
rely on the fact that in vitro (27), at low dialysate flow rate, the saturation of the
dialysate in urea is constant, and therefore that the k can be represented by the formula: k
= ax Qd (with a: saturation constant and Qd: dialysate flow) Therefore, the investigator
propose the following formula: Dialysis dose = a x Qd x t / V This is a new measurement
method with important clinical relevance since it avoids two blood tests and two biological
tests.
The investigator would therefore like to assume that the measure of kt / V would be
equivalent between the formula the investigator would like to test and the conventional
formula, either: a x Qd x t / V ≡ kt / V Daugirdas2
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05700851 -
Immuno-nutrition Supplementation in Haemodialysis
|
N/A | |
Recruiting |
NCT02616627 -
Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
|
||
Completed |
NCT01464190 -
A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients
|
Phase 3 | |
Recruiting |
NCT06040281 -
Smart and Fit for Kidney Transplantation
|
N/A | |
Active, not recruiting |
NCT03535922 -
Evaluation of Routinely Measured Patient-reported Outcomes in Hemodialysis Care
|
N/A | |
Completed |
NCT04622709 -
Pilot Study of Loop Diuretics Among Individuals Receiving Hemodialysis
|
Phase 2 | |
Completed |
NCT04585607 -
Potential Benefits of Expanded Hemodialysis in Prevention of Sarcopenia
|
Phase 4 | |
Completed |
NCT03182699 -
Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT03942744 -
The Effect of High-flux Hemodialysis and On-line Hemodiafiltration on Endothelial Function.
|
N/A | |
Completed |
NCT04549597 -
Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia
|
Phase 4 | |
Recruiting |
NCT04659525 -
Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia
|
Phase 4 | |
Completed |
NCT04125537 -
Pathways Project: Kidney Supportive Care
|
||
Recruiting |
NCT03347773 -
Oral Nutritional Supplement Intervention Among Hemodialysis Patients With Sarcopenic Obesity
|
N/A | |
Recruiting |
NCT04397653 -
Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients
|
Phase 4 | |
Active, not recruiting |
NCT03938285 -
Effect of Hemodiafiltration Plus MCOs on Uremic Toxins Removal
|
N/A | |
Completed |
NCT03525223 -
Modulation of Tissue Sodium in Hemodialysis Patients
|
N/A | |
Completed |
NCT01324128 -
A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients
|
Phase 3 | |
Not yet recruiting |
NCT04600193 -
a Randomized Controlled Trial of the Intake of Organic and Inorganic Phosphate in Peritoneal Dialysis Patients
|
N/A | |
Not yet recruiting |
NCT06225544 -
Lumasiran in Hyperoxalaemic Patients on Haemodialysis
|
Phase 2 | |
Recruiting |
NCT05209880 -
Advance Care Planning in the Emergency Department
|
N/A |